RNS Number:3901F
Celsis International PLC
09 October 2007



                            CELSIS INTERNATIONAL PLC

                            NOTIFICATION OF RESULTS


9 October 2007: Celsis International plc, the life sciences products and
laboratory services company, will announce its interim results for the six
months ended 30 September 2007 on Wednesday 31 October 2007.


There will be a presentation to analysts on the day at 9.30am, held at Financial
Dynamics, Holborn Gate, 26 Southampton Buildings, London, WC2A 1PB.  For more
information please contact Gemma Cross Brown on +44 (0)207 269 7125.



Enquiries:

Celsis International plc                                  Tel: 01223 598 428
Jay LeCoque, Chief Executive Officer
Jenny Parsons, Corporate Communications

Financial Dynamics                                        Tel: 020 7831 3113
Lara Mott
Ben Atwell


Notes to editors


Celsis International plc

Celsis International plc is a world leading provider of innovative life science
products and laboratory services to the pharmaceutical, biopharmaceutical, and
consumer products industries through its three business areas; rapid detection,
analytical and drug development services and ADME-Tox in vitro technologies.
The company is listed on the London Stock Exchange (CEL.L).



Each division of Celsis International plc has the capacity to deliver
substantial time and cost savings to its customers, in addition to ensuring
product quality and safety for consumers.  Using proprietary technology, the
Celsis Rapid Detection division provides diagnostic systems for the rapid
detection of contamination.  These systems provide significant economic value by
reducing the time it takes to test and release raw materials, in process and
finished goods to market.  Celsis Analytical Services division provides cost
effective outsourced laboratory testing services to pharmaceutical and
biopharmaceutical companies.  Its comprehensive service offerings include a full
spectrum of laboratory services from drug development and discovery to
analytical chemistry and biological sciences to stability storage and testing.
Celsis In Vitro Technologies (Celsis IVT) supplies in vitro testing products to
the pharmaceutical and biotechnology industries.  IVT's in vitro products screen
drug compounds early in the discovery process, thereby reducing the time and
cost of drug development.



Further information can be found on its website at www.celsis.com.




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

NORZGMGGMLKGNZM
Celadon Pharmaceuticals (LSE:CEL)
Historical Stock Chart
From Sep 2024 to Oct 2024 Click Here for more Celadon Pharmaceuticals Charts.
Celadon Pharmaceuticals (LSE:CEL)
Historical Stock Chart
From Oct 2023 to Oct 2024 Click Here for more Celadon Pharmaceuticals Charts.